BDX 10-Q Quarterly Reports

Becton, Dickinson and Company (BDX) reported a modest increase in revenues for the fiscal first quarter ending December 31, 2025, with total revenues reaching $5.252 billion, up 1.6% from the prior year. This growth was primarily driven by favorable foreign currency impacts and moderate volume increases, despite some pricing headwinds. Net income rose to $382 million, resulting in diluted earnings per share of $1.34, a significant increase from $1.04 in the prior year, reflecting improved operational performance and the favorable impact of foreign currency. The company also announced the completion of a major transaction: the spin-off of its Biosciences and Diagnostic Solutions business, combined with Waters Corporation, which resulted in a significant cash distribution of $4 billion to BD. This strategic move is expected to reshape the company's future focus and financial structure. Operationally, the company saw varied performance across its segments. While Connected Care and Interventional segments showed strong revenue growth, driven by specific product lines like Advanced Patient Monitoring and Peripheral Intervention respectively, the Medical Essentials segment experienced slight declines. The Life Sciences segment, which is being divested, saw a notable decrease in revenues. Looking ahead, BD is prioritizing innovation, commercial excellence, and operational efficiency under its 'Excellence Unleashed' strategy. The significant cash influx from the Waters transaction provides ample opportunity for strategic deployment, including accelerated share repurchases and debt reduction, aiming to enhance shareholder value.

Becton, Dickinson and Company (BDX) reported solid revenue growth for the third quarter of fiscal year 2025, with total revenues reaching $5.509 billion, a 10.4% increase year-over-year. This growth was significantly bolstered by the acquisition of Advanced Patient Monitoring and organic growth across its Medical and Interventional segments, which offset a slight decline in Life Sciences revenue. Diluted earnings per share also saw an increase to $2.00 from $1.68 in the prior-year period, demonstrating improved profitability. The company continues to execute its BD 2025 strategy, focusing on growth, simplification, and empowerment, and is strategically managing its capital through dividends and share repurchases. A significant strategic development is the definitive agreement to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, structured as a Reverse Morris Trust. This transaction is expected to create a focused life science and diagnostics leader, with BD receiving a substantial cash distribution. While the transaction is projected to be tax-free for BD and its shareholders, its completion is subject to regulatory and shareholder approvals and is anticipated around the end of the first quarter of calendar year 2026. Management remains focused on navigating global economic factors and supply chain dynamics while pursuing innovation and operational efficiency.

Becton Dickinson & Co. (BDX) reported revenues of $5.272 billion for the third quarter of fiscal year 2025, a 4.5% increase year-over-year. This growth was primarily driven by the acquisition of Advanced Patient Monitoring and solid performance in the Medical and Pharmaceutical Systems segments, though partially offset by challenges in the Life Sciences and Interventional segments. Net income for the quarter was $308 million, down from $537 million in the prior year period, resulting in diluted EPS of $1.07 compared to $1.85. The company announced its intention to separate its Biosciences and Diagnostic Solutions businesses, a move expected to be completed in fiscal year 2026, which aims to unlock shareholder value. Despite revenue growth, the decrease in net income was influenced by factors including purchase accounting adjustments, increased restructuring costs, and higher interest expenses related to recent acquisitions. BDX's balance sheet shows $8.67 billion in current assets and $7.69 billion in current liabilities as of March 31, 2025. The company generated $857 million in net cash from operating activities for the first six months of fiscal year 2025, a decrease from $1.369 billion in the prior year, attributed to changes in working capital, including higher inventory levels and lower accounts payable and accrued expenses. Significant financing activities included $876 million in debt payments and $750 million in share repurchases. The company continues to return capital to shareholders through dividends, with $600 million paid in the first six months of fiscal year 2025.

Becton Dickinson & Co. (BDX) reported a 9.8% increase in revenue for the first quarter of fiscal year 2025, reaching $5.168 billion, driven by a 5.7% boost from the recent acquisition of Advanced Patient Monitoring and organic growth across its segments. Net income grew to $303 million ($1.04 EPS) from $281 million ($0.97 EPS) in the prior year's quarter, indicating a positive trend in profitability. The company also announced its intention to separate its Biosciences and Diagnostic Solutions businesses, aiming to enhance shareholder value. This strategic move, expected to be completed in fiscal year 2026, suggests a focus on optimizing its portfolio and unlocking potential value. While the company navigates various legal and regulatory matters, including ongoing product liability claims and FDA inquiries, its financial performance shows resilience, supported by strong operational execution and strategic acquisitions.

Becton Dickinson and Company (BDX) reported solid revenue growth in the third quarter of fiscal year 2024, with total revenues reaching $4.99 billion, a 2.3% increase year-over-year. This growth was driven by strong performance in the Medical and Interventional segments, particularly in Medication Delivery Solutions and Urology and Critical Care, respectively. Net income for the quarter was $487 million, resulting in diluted earnings per share of $1.68, an improvement from $1.36 in the prior year's quarter. The company continues to strengthen its financial position, demonstrated by a significant increase in cash and equivalents and the successful issuance of new debt to fund strategic initiatives. A significant development during the quarter was the announcement of the definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This strategic acquisition is expected to enhance BD's smart connected care solutions and is anticipated to close by the end of calendar year 2024, subject to regulatory approvals. The company also provided updates on ongoing legal matters, including product liability claims and regulatory investigations, noting a $50 million charge related to an SEC investigation into Alaris infusion pumps. Overall, BDX demonstrated resilience and strategic foresight, balancing operational execution with significant growth opportunities.

Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter of fiscal year 2024, with total revenues increasing by 4.6% year-over-year to $5.045 billion. This growth was driven by broad-based strength across its segments, particularly the Interventional segment, which saw a 9.0% increase in revenue, and the Medical segment's 3.8% rise. Net income applicable to common shareholders rose to $537 million from $438 million in the prior year, and diluted Earnings Per Share (EPS) improved to $1.85 from $1.53. The company's financial condition remains robust, with operating cash flows of $1.369 billion for the first six months of fiscal 2024. BDX also continued to return capital to shareholders through dividends, distributing $550 million. Despite some headwinds such as increased raw material and labor costs, and specific market dynamics in China, the company demonstrated effective cost management, with selling, general, and administrative expenses decreasing as a percentage of revenue. The company's outlook remains focused on its BD 2025 strategy centered on growth, simplification, and empowerment.

Becton Dickinson and Company (BDX) reported a 2.6% increase in revenue for the third quarter of fiscal year 2024, reaching $4.706 billion, compared to $4.586 billion in the prior year. This growth was driven by price increases and a favorable foreign currency translation, partially offset by a decrease in volume and the impact of selling off the Surgical Instrumentation platform. Net income saw a significant decrease to $281 million ($0.96 per diluted share) from $509 million ($1.70 per diluted share) in the comparable prior-year period. This decline is primarily attributed to specified items, including integration and restructuring costs, purchase accounting adjustments, and European regulatory initiative-related costs, which had a substantial negative impact on earnings per share. The company's financial performance reflects ongoing strategic initiatives, including simplification and cost-saving measures, which contributed to integration and restructuring expenses. Despite the year-over-year decrease in net income, operating cash flow remained strong at $855 million. BDX also continued to return capital to shareholders through dividends and significant share repurchases, totaling $500 million in accelerated share repurchase agreements during the quarter. The company's balance sheet shows a decrease in cash and equivalents to $1.180 billion, but the overall financial position remains robust with adequate liquidity and access to financing facilities.

Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter of fiscal year 2023, with total revenues reaching $4.878 billion, a 5.1% increase year-over-year. This growth was driven by broad-based performance across its Medical, Life Sciences, and Interventional segments, with particular strength noted in areas like pharmacy automation and pharmaceutical systems. Despite revenue gains, operating income from continuing operations saw a slight decrease to $549 million from $537 million in the prior year's quarter, and net income applicable to common shareholders was $392 million compared to $338 million. The company's diluted EPS from continuing operations increased to $1.36. The company continues to manage its operational costs effectively and returned significant value to shareholders through dividends. BDX also made progress on strategic initiatives, including the sale of its Surgical Instrumentation platform, highlighting a focus on portfolio optimization.

Becton Dickinson and Company (BDX) reported third quarter fiscal year 2023 results with revenues of $4.82 billion, a modest 1.5% increase year-over-year, or 4.1% on a foreign currency-neutral basis. This growth was driven by strong performance in the Medical and Interventional segments, partially offset by a significant decline in COVID-19 related testing revenues within the Life Sciences segment. Net income from continuing operations rose to $460 million ($1.53 per diluted share), up from $390 million ($1.28 per diluted share) in the prior year, indicating improved profitability. The company continues to navigate inflationary pressures and supply chain challenges while focusing on its 'grow, simplify, and empower' strategy, investing in innovation and operational efficiency. Financially, BDX demonstrated solid liquidity with cash and equivalents of $1.98 billion. The company also actively managed its debt, issuing new notes and maintaining compliance with its credit facility covenants. While overall revenue growth was moderate, the underlying segment performance shows resilience, with acquisitions like Parata Systems contributing to growth in the Medication Management Solutions unit. Investors should note the ongoing legal proceedings and regulatory matters, particularly concerning product liability and the Alaris infusion pump, which continue to be areas of focus for management and potential risk.

Becton Dickinson and Company (BDX) reported revenues of $4.586 billion for the quarter ended December 30, 2022, a decrease of 2.8% compared to the prior year. This decline was primarily driven by a significant reduction in COVID-19 testing revenue and unfavorable foreign currency translation, which offset underlying volume and pricing improvements in certain segments. The company experienced a net income of $509 million, or $1.70 per diluted share, compared to $677 million ($2.28 per diluted share) in the same period last year. The year-over-year decrease in net income was impacted by the discontinuation of COVID-19 related testing revenue and ongoing inflationary pressures on raw materials, labor, and freight costs. Despite the top-line decline, BD demonstrated resilience with positive volume growth driven by acquisitions and strong demand in its Medical and Interventional segments, particularly in Medication Management Solutions, Pharmaceutical Systems, and Peripheral Intervention. The Life Sciences segment saw a notable decrease in revenue, largely attributable to the drop in COVID-19 testing sales. The company continues to manage costs and navigate macroeconomic challenges, including inflation and supply chain constraints, while also returning capital to shareholders through dividends. Significant ongoing legal matters and regulatory scrutiny, particularly related to the Alaris infusion pump, require continued monitoring.

Becton Dickinson and Company (BDX) reported second-quarter fiscal year 2022 revenues of $4.641 billion, a slight increase of 0.7% year-over-year, driven by strong core product demand across its Medical and Interventional segments. The Life Sciences segment saw a notable revenue decline, primarily due to the lapping of significant COVID-19 testing sales from the prior year. Despite inflationary pressures on raw materials and freight, the company demonstrated resilience by improving gross profit margins through price management and cost efficiencies. The company completed the spin-off of its Diabetes Care business (Embecta Corp.) on April 1, 2022, with historical results now reflected as discontinued operations. This strategic move is expected to allow BDX to focus on its core medical technology segments. While the company faces ongoing macroeconomic challenges including inflation and supply chain disruptions, it continues to invest in growth initiatives and return value to shareholders through dividends. Management remains focused on its 'grow, simplify and empower' strategy to navigate the current environment.

Becton Dickinson and Company (BDX) reported its fiscal second-quarter 2022 results, showcasing a modest revenue increase of 2.1% year-over-year to $5.011 billion. This growth was primarily driven by robust performance in the Medical and Interventional segments, with the Life Sciences segment experiencing a decline, largely due to a significant drop in COVID-19 diagnostic testing revenue compared to the prior year. Despite the revenue increase, net income saw a substantial rise to $454 million from $299 million in the same period last year, translating to diluted EPS of $1.50, up from $0.94. This improvement in profitability was aided by the resolution of certain legal matters that impacted the prior year's results, as well as cost management initiatives. The company also announced the completion of the spin-off of its Diabetes Care business (Embecta Corp.) on April 1, 2022. This strategic move is expected to allow BD to focus on its core businesses. While managing ongoing inflationary pressures and supply chain disruptions remains a key focus, BD generated strong operating cash flow and continues to return capital to shareholders through dividends. Investors should monitor the company's ability to navigate macroeconomic headwinds, integrate strategic acquisitions, and the impact of ongoing litigation and regulatory matters.

Becton, Dickinson and Company (BDX) reported revenues of $4.995 billion for the three months ended December 31, 2021, a decrease of 6.0% compared to the prior year period. This decline was largely driven by a significant reduction in COVID-19 diagnostic testing revenues, which were $185 million in the current quarter compared to $866 million in the prior year. Despite the revenue decrease, the company managed operating costs effectively, resulting in a net income of $677 million, or $2.28 per diluted share, compared to $1,003 million, or $3.35 per diluted share, in the prior year. The company is actively managing its strategic direction, including the planned spin-off of its Diabetes Care business, Embecta Corp., which is expected to be completed in the first half of calendar year 2022. The company also reported ongoing investments in research and development and strategic acquisitions to support its long-term growth strategy, anchored in its BD 2025 pillars of grow, simplify, and empower. However, persistent challenges in global supply chains, including rising raw material and freight costs, along with labor shortages, are impacting gross profit margins and operating expenses.

Becton Dickinson & Co. (BDX) reported a strong financial performance for the quarter ending June 30, 2021, with revenues increasing significantly by 26.9% year-over-year to $4.89 billion. This growth was driven by a broad-based increase in volume across its Medical, Life Sciences, and Interventional segments, with notable contributions from COVID-19 diagnostic testing solutions and a recovery in elective medical procedures. The company's profitability also saw a substantial improvement, with net income more than doubling to $525 million compared to $286 million in the prior-year period. Diluted Earnings Per Share (EPS) rose to $1.72 from $0.97. The company generated robust operating cash flow of $3.7 billion for the nine months ended June 30, 2021, demonstrating strong operational efficiency and financial discipline. BDX also announced its intention to spin off its Diabetes Care business in the first half of calendar year 2022, a strategic move aimed at unlocking value and focusing resources. However, investors should note the ongoing legal and regulatory matters, particularly product liability claims related to hernia repair devices and other products, which led to a significant charge of $296 million in the current quarter. While the company is actively managing these issues, they represent a material contingent liability. Despite these challenges, the company's diversified business segments and strategic initiatives, including the planned spin-off, position it for continued growth and value creation.

Becton, Dickinson and Company (BDX) reported solid revenue growth in its second quarter fiscal year 2021, with a 15.4% increase year-over-year, reaching $4.907 billion. This growth was largely driven by strong performance in the Life Sciences segment, fueled by COVID-19 diagnostic testing solutions, and continued strength in Medical and Interventional segments. The company also announced its intention to spin off its Diabetes Care business into a separate publicly traded entity, expected to be completed in the first half of calendar year 2022. This strategic move aims to position both BD and the standalone Diabetes Care business for enhanced capital allocation and focused growth. While overall financial performance appears positive, investors should remain aware of significant ongoing product liability matters, particularly concerning hernia repair and women's health devices, which resulted in a substantial $296 million charge during the quarter. The company continues to navigate these legal challenges and other regulatory matters.

Becton, Dickinson and Company (BDX) reported a significant increase in revenue and net income for the three months ended December 31, 2020, compared to the same period in the prior year. This surge was primarily driven by strong demand for COVID-19 diagnostic testing solutions, particularly within the Life Sciences segment. The company also saw revenue growth across its Medical and Interventional segments, benefiting from increased healthcare utilization and specific product demands related to the pandemic. Despite the overall positive financial performance, investors should note the ongoing impact of the COVID-19 pandemic on global supply chains and demand for non-essential procedures. The company continues to manage significant legal and regulatory challenges, particularly concerning product liability claims and ongoing investigations, which could materially affect future results. However, BDX demonstrated robust cash flow generation and maintained a solid liquidity position.

Becton, Dickinson and Company (BDX) reported revenues of $3.86 billion for the third quarter of fiscal year 2020, a decrease of 11.4% year-over-year. This decline was primarily attributed to the COVID-19 pandemic, which negatively impacted procedural volumes and overall healthcare demand, resulting in an estimated $600 million reduction in revenue. Despite the revenue challenges, the company took proactive steps to manage its financial position, including increasing its revolving credit facility and issuing equity. BD also continued its commitment to shareholder returns through dividend payments. The company's performance varied by segment, with the Life Sciences segment seeing some offset from COVID-19 testing solutions, while Medical and Interventional segments faced headwinds from reduced elective procedures and non-COVID-19 related medical device demand. BD highlighted its efforts in developing and distributing COVID-19 diagnostic tests and its preparedness for a potential future vaccination campaign, demonstrating its role in addressing the pandemic's healthcare needs.

Becton Dickinson & Co. (BDX) reported revenues of $4.25 billion for the three months ended March 31, 2020, a 1.4% increase year-over-year, primarily driven by volume growth, though this was partially offset by foreign currency translation impacts. The company experienced a net income of $183 million, or $0.53 per diluted share, a significant improvement from a net loss of $18 million in the prior year's comparable quarter. This improvement was largely due to a substantial reduction in "Other operating expense, net," which included significant charges in the prior year related to product liability matters and a business divestiture gain. The COVID-19 pandemic began to impact BDX's operations in the quarter, leading to an estimated $56 million unfavorable impact on consolidated revenues. While certain segments saw benefits, others, particularly those tied to elective medical procedures like the Interventional segment, experienced declines. Management has implemented cost containment measures and secured additional credit facilities to preserve financial flexibility amidst the evolving global economic conditions. Despite the external uncertainties, the company maintained a strong liquidity position.

Becton, Dickinson and Company (BDX) reported a modest revenue increase of 1.6% to $4.225 billion for the three months ended December 31, 2019, compared to the prior year. This growth was primarily driven by volume increases across all three business segments: Medical, Life Sciences, and Interventional. However, net income applicable to common shareholders significantly decreased to $240 million ($0.87 per diluted share) from $562 million ($2.05 per diluted share) in the comparable prior-year period. This decline was heavily influenced by significant "specified items" impacting both periods, including a substantial product recall charge of $59 million in the current quarter and a large gain from a business divestiture in the prior year, along with a higher effective tax rate in the current period. The balance sheet shows total assets of $51.95 billion and total liabilities of $30.75 billion. Notably, short-term debt increased substantially from $1.31 billion to $2.46 billion, while long-term debt decreased. The company generated strong operating cash flow of $713 million, an improvement from the previous year, indicating healthy operational cash generation despite the dip in net income.

Becton Dickinson & Co. (BDX) reported for the fiscal quarter ended June 30, 2019, with revenues of $4.35 billion, a 1.7% increase year-over-year. This growth was primarily driven by volume increases across its Medical, Life Sciences, and Interventional segments, partially offset by unfavorable foreign currency translation and pricing pressures. Net income for the quarter was $451 million, or $1.51 per diluted share, a decrease from $594 million, or $2.03 per diluted share, in the prior year's quarter. This decline is largely attributable to a significant pre-tax charge of $331 million related to product liability matters, as well as higher acquisition and restructuring costs associated with the Bard acquisition. Despite these charges, the company generated strong operating cash flow of $1.96 billion for the first nine months of the fiscal year, underscoring its operational resilience. The company continues to return capital to shareholders through dividends, with $737 million paid out in the first nine months.

Becton Dickinson & Co. (BDX) reported its first quarter results for fiscal year 2019, showing a slight year-over-year decrease in total revenues to $4.195 billion from $4.222 billion. This revenue decline was primarily attributed to an unfavorable foreign currency translation impact of approximately 2.7% and a 1% impact from the divestiture of the Advanced Bioprocessing business. Despite the revenue dip, the company demonstrated resilience with positive volume growth across all three segments: Medical, Life Sciences, and Interventional. The Medical segment saw notable growth in Medication Management Solutions, while Life Sciences benefited from Preanalytical Systems and Biosciences, and Interventional saw strength in Peripheral Intervention and Urology and Critical Care. The company incurred a significant pre-tax charge of $331 million related to certain product liability matters, impacting the "Other operating expense, net" line item. This charge, combined with other factors, led to a net income of $20 million for the quarter, a substantial improvement from the net loss of $12 million in the prior-year period. Diluted earnings per share were $(0.07), compared to $(0.19) in the prior year. The company continued to generate strong operating cash flow, amounting to $1.027 billion for the six months ended March 31, 2019, supporting its ongoing commitment to returning value to shareholders through dividends.

Becton, Dickinson and Company (BDX) reported strong revenue growth of 35.1% year-over-year to $4.16 billion for the three months ended December 31, 2018. This significant increase was largely driven by the acquisition of C.R. Bard, Inc. (Bard), which contributed approximately 33% to the revenue growth, with the remainder attributed to organic volume growth and price. Despite the strong top-line performance, the company faced increased operating costs, including higher raw material costs and amortization expenses related to the Bard acquisition, which impacted gross profit margin. However, the company generated positive operating income and a net income of $599 million, a significant turnaround from a net loss in the prior year. The company also reported healthy cash flow from operations and continued to return value to shareholders through dividends.

Becton, Dickinson & Co. (BDX) reported strong revenue growth in the third quarter of fiscal year 2018, driven significantly by the acquisition of C.R. Bard, Inc., which closed in late 2017. The combined entity generated $4.278 billion in revenue, a 41.0% increase year-over-year, with Bard contributing approximately 32.4% of this growth. The company has realigned its business segments, now operating under BD Medical, BD Life Sciences, and BD Interventional, with the latter now encompassing the majority of Bard's former product offerings. Despite the integration of Bard, the company experienced growth in its established segments as well, with Medical seeing a 20.0% increase and Life Sciences growing by 8.2% in the quarter on a reported basis. However, the company also faces significant ongoing litigation, particularly related to product liability claims inherited from Bard, which have led to substantial accruals for potential losses. Management anticipates future charges related to these matters could materially impact results.

Becton Dickinson & Co. (BDX) reported its fiscal second quarter 2018 results, heavily influenced by the recent acquisition of C.R. Bard, Inc. Total revenues surged by 42.2% year-over-year to $4.222 billion, with approximately 33% of this growth attributed to the Bard acquisition. The company experienced a net loss of $12 million, or $(0.19) per diluted share, compared to a net income of $344 million, or $1.58 per diluted share, in the prior-year period. This swing to a loss was significantly impacted by acquisition-related expenses, including a substantial $422 million inventory step-up adjustment for Bard's inventory. Despite the near-term net loss, the underlying operational performance shows positive volume growth and contributions from key segments. The balance sheet reflects the significant impact of the Bard acquisition, with total assets increasing substantially to $54.57 billion from $37.73 billion at fiscal year-end 2017, driven by increases in goodwill, developed technology, and property, plant, and equipment. Long-term debt also increased significantly to fund the acquisition. The company continues to manage its cash flow effectively, with operating activities providing $1.017 billion in cash over the first six months. Investors should monitor the integration of Bard, ongoing litigation matters, and the impact of the new U.S. tax legislation, which has resulted in provisional expense recognition.

Becton Dickinson & Co. (BDX) reported its financial results for the fiscal quarter ending December 30, 2017. The period was significantly marked by the completion of the acquisition of C.R. Bard, Inc. on December 29, 2017, for approximately $25 billion. This acquisition is expected to be transformative for the company, creating a leading medical technology entity. Financially, the quarter showed a reported net loss of $136 million, or -$0.76 per diluted share, a stark contrast to the $562 million net income, or $2.58 per diluted share, reported in the prior year's comparable quarter. This net loss was heavily influenced by substantial acquisition-related costs, including transaction and integration expenses, as well as provisional tax expenses stemming from the new U.S. tax legislation. Despite the reported net loss, the company experienced revenue growth of 5.4% year-over-year, reaching $3.08 billion, driven by volume increases in both its Medical and Life Sciences segments, and a favorable foreign currency translation impact. The balance sheet reflects a significant increase in assets and liabilities due to the Bard acquisition, with total assets growing to $55.4 billion from $37.7 billion at the prior quarter's end. Long-term debt also increased substantially to fund the acquisition. While the immediate financial results were impacted by the large acquisition, investors should focus on the strategic benefits and future growth prospects presented by the combined entity.

Becton Dickinson & Co. (BDX) reported a net loss of $132 million for the third quarter of fiscal year 2017, compared to a net income of $390 million in the prior year's quarter. This loss was largely driven by a significant $741 million non-cash charge related to the modification of dispensing equipment lease contracts, coupled with ongoing integration and transaction costs associated with the pending acquisition of C.R. Bard, Inc. Despite the quarterly loss, the company generated $1.424 billion in cash from operations for the first nine months of the fiscal year, highlighting its operational cash-generating capabilities. Significant financing activities occurred, including substantial debt and equity issuances to fund the Bard acquisition, resulting in a large increase in cash and equivalents to $13.852 billion. Investors should monitor the progress and impact of the C.R. Bard acquisition, as well as the ongoing operational performance of its Medical and Life Sciences segments.

Becton, Dickinson and Company (BDX) reported its fiscal second quarter 2017 results, showcasing a slight decrease in revenue primarily due to the divestiture of its Respiratory Solutions business. Despite this, the company demonstrated resilience with volume growth in its continuing operations, particularly in the Medical and Life Sciences segments. The company highlighted ongoing investments in research and development and geographic expansion as drivers for future growth. Financially, BDX maintained a strong position with solid operating cash flows, enabling continued returns to shareholders through dividends and share repurchases. A significant development announced post-quarter was the definitive agreement to acquire C.R. Bard, Inc., a move expected to create a leading medical technology company. The company navigated a complex operating environment, including foreign currency translation headwinds, but emphasized its ability to adapt and grow its core businesses. The financial results were also impacted by specific items, including a significant reversal of litigation reserves due to a favorable appellate court decision, which boosted net income. Investors should note the strategic direction towards enhanced market position through acquisitions, alongside disciplined operational execution.

Becton, Dickinson and Company (BDX) reported for the quarter ending December 31, 2016, a decrease in revenue of 2.1% to $2.922 billion, largely attributed to the divestiture of the Respiratory Solutions business. Despite the revenue dip, the company demonstrated robust operating performance, with operating income increasing significantly compared to the prior year, bolstered by improved gross profit margins and cost efficiencies. Net income saw a substantial rise to $562 million, or $2.58 per diluted share, up from $229 million, or $1.06 per diluted share, in the prior year's period. This improvement was notably influenced by the reversal of a significant litigation reserve. The company actively managed its capital structure during the quarter, issuing euro-denominated debt and repurchasing substantial amounts of its long-term debt. Shareholder returns were maintained through dividend payments and significant share repurchases under an accelerated share repurchase program. While facing ongoing challenges such as foreign currency fluctuations and pricing pressures, BDX's strategic focus on core business expansion, innovation, and operational efficiency positions it to navigate the dynamic healthcare landscape.

Becton Dickinson & Co. (BDX) reported solid financial results for the third quarter of fiscal year 2016, with revenues increasing by 2.5% to $3.198 billion, driven primarily by volume growth across both its Medical and Life Sciences segments. The company demonstrated improved operating income and a strengthened balance sheet, with cash flow from operations remaining robust. The successful integration of CareFusion continues to be a key focus, and management highlighted ongoing investments in research and development to fuel future growth. While the company navigates various market dynamics, including foreign currency fluctuations and pricing pressures, its strategic initiatives and strong operational execution are evident. Investors should note the company's continued commitment to returning value through dividends, with no share repurchases in the reported period, and its strong liquidity position. The company also provided pro forma results for the nine-month period, giving a clearer picture of the combined entity's performance.

Becton Dickinson & Co. (BDX) reported a significant increase in revenue for the third quarter of fiscal year 2016, reaching $3.07 billion, a 49.6% rise compared to the prior year. This growth was largely driven by the inclusion of CareFusion's results, acquired in March 2015, which contributed $1.017 billion in revenue. Excluding the impact of foreign currency translation, the company saw a substantial 55.1% revenue increase on a constant currency basis. Despite the strong revenue growth, investors should note the impact of acquisition-related costs, particularly the amortization of intangible assets from the CareFusion acquisition, which affected gross profit margins. The company generated $1.02 billion in operating cash flow for the first six months of the fiscal year, demonstrating solid cash generation. BDX continued to return value to shareholders through dividends, distributing $280 million in the first half of the fiscal year, though no shares were repurchased during this period. Overall, the report highlights the significant integration of CareFusion and its impact on top-line growth, while managing the associated costs.

Becton Dickinson & Co. (BDX) reported its first quarter fiscal year 2016 results on February 4, 2016, for the period ending December 31, 2015. The company experienced a significant revenue increase of 45.6% year-over-year, reaching $2.986 billion. This growth was primarily driven by the inclusion of CareFusion's results, acquired in March 2015, which contributed $1.016 billion in revenue and $137 million in operating income to the Medical segment. Excluding the impact of foreign currency fluctuations, revenue grew by a robust 53.5% on a constant currency basis. Despite the substantial revenue growth, net income decreased to $229 million from $236 million in the prior year, leading to a dip in diluted earnings per share to $1.06 from $1.20. This decline was impacted by higher operating costs, including acquisition-related expenses ($121 million), increased R&D spending, and a significant increase in intangible asset amortization related to the CareFusion acquisition. The company generated $463 million in cash from operating activities, demonstrating solid cash flow generation. BDX also continued to return value to shareholders through dividends, paying out $140 million in the quarter. Investors should closely monitor the integration of CareFusion and the ongoing impact of acquisition-related costs and amortization on profitability.

Becton, Dickinson and Company (BDX) reported its third-quarter and nine-month results for the period ending June 30, 2015. The most significant event for the quarter was the completion of the acquisition of CareFusion Corporation on March 17, 2015, for approximately $12.5 billion. This acquisition substantially reshaped the company's financial statements, leading to a significant increase in total assets and liabilities, particularly in intangible assets and goodwill. Financially, the third quarter saw a substantial increase in revenue, driven primarily by the inclusion of CareFusion's results. However, net income and earnings per share were significantly lower compared to the prior year, largely due to the impact of "specified items" related to the acquisition, including transaction, integration, and financing costs. These items, along with purchase accounting adjustments, masked the underlying operational performance. The company also saw a substantial increase in long-term debt to finance the acquisition, leading to higher interest expenses. Investors should closely examine the "specified items" and pro forma information to understand the operational performance before these significant one-time costs.

Becton, Dickinson and Company (BDX) reported its financial results for the fiscal second quarter ended March 31, 2015. The quarter was marked by a significant event: the completion of the acquisition of CareFusion Corporation on March 17, 2015. This transformative acquisition, valued at approximately $12.5 billion, is expected to create a global leader in medication management and patient safety solutions. Financially, the company experienced a 1.0% decrease in revenue to $2.051 billion compared to the prior year, largely due to an unfavorable foreign currency translation impact of 5.9%. Despite this revenue dip, operational performance showed resilience, with strong sales in safety-engineered products and continued growth in key segments. Net income for the quarter was $216 million, down from $287 million in the prior year, resulting in diluted earnings per share of $1.08, compared to $1.45. The company also reported significant acquisition-related costs, including financing, transaction, integration, and restructuring expenses. The balance sheet reflects the impact of the CareFusion acquisition, with substantial increases in goodwill, intangible assets, and long-term debt. The company's financial position remains strong, with $2.0 billion in cash and equivalents and short-term investments at quarter-end. BDX is focused on integrating CareFusion and leveraging the combined entity's strengths to drive future growth and efficiencies.

Becton Dickinson and Company (BDX) reported its fiscal first quarter 2015 results for the period ending December 31, 2014. The company announced a 1.8% increase in revenue to $2.051 billion, driven by volume growth partially offset by unfavorable foreign currency translation. Net income decreased to $236 million from $271 million in the prior year period, leading to diluted earnings per share of $1.20, down from $1.37. This decrease was influenced by significant acquisition-related costs, litigation charges, and financing expenses associated with the pending acquisition of CareFusion Corporation, which was announced during the quarter. The balance sheet shows a significant increase in cash and equivalents to $8.54 billion from $1.86 billion, largely due to proceeds from debt issuance to finance the CareFusion acquisition. Long-term debt also saw a substantial rise to $9.94 billion from $3.77 billion. Investors should note the strategic shift with the pending acquisition of CareFusion, which is expected to close by the second quarter of fiscal year 2015, creating a larger entity focused on medication management and patient safety. While the company's financial position remains strong, the increased debt and integration efforts related to the acquisition will be key areas to monitor.

Becton Dickinson & Co. (BDX) reported solid performance for the quarter ended June 30, 2014, with revenues increasing by 5.1% to $2.157 billion, driven by growth in the Medical and Biosciences segments. The company maintained a strong financial position, with cash flows from operating activities totaling $1.207 billion for the nine-month period and $2.6 billion in cash and short-term investments at quarter-end. Diluted earnings per share from continuing operations saw a notable increase to $1.65 compared to $1.47 in the prior year's quarter, reflecting operational improvements and favorable segment performance. Despite some challenges in the U.S. Diagnostics segment due to ongoing weakness in the Women's Health and Cancer platform, overall revenue growth was bolstered by international sales and strong performance in emerging markets. The company continued to return value to shareholders through share repurchases and dividends, underscoring a commitment to financial discipline and shareholder returns. While facing some ongoing litigation and economic uncertainties, BDX demonstrated resilience and strategic focus on core business expansion and innovation.

Becton Dickinson & Co. (BDX) reported financial results for the quarter ended March 31, 2014, showcasing moderate revenue growth driven by its Medical and Biosciences segments, while the Diagnostics segment experienced a slight decline. Overall revenue increased by 3.6% year-over-year to $2.072 billion, supported by volume increases, though partially offset by unfavorable foreign exchange. The company demonstrated solid operating income growth, particularly in the Medical segment, which benefited from improved gross profit margins due to cost efficiencies and favorable product mix. Despite some headwinds in the Diagnostics segment, such as lower sales from the Women’s Health and Cancer platform and charges related to distributor termination, BDX maintained a strong financial position. The company generated robust operating cash flow and continued to return value to shareholders through share repurchases and dividends. Investments in research and development remain a priority, with a notable increase in spending within the Biosciences segment due to asset write-offs related to product development discontinuance.

Becton Dickinson & Co. (BDX) reported its first quarter fiscal year 2014 results, ending December 31, 2013. The company demonstrated solid revenue growth, with total revenues reaching $2.015 billion, a 6.0% increase compared to the prior year. This growth was driven by volume increases across all three business segments: Medical, Diagnostics, and Biosciences, with particular strength noted in the Medical and Biosciences segments. The company continued to focus on returning value to shareholders, repurchasing $189 million of its common stock and paying $106 million in dividends during the quarter. Despite overall revenue growth, operating income faced some pressure due to factors such as unfavorable foreign currency translation, higher start-up costs, amortization of intangible assets, and increased raw material costs. A significant factor impacting profitability was the U.S. medical device excise tax, which contributed $14 million or $0.05 per diluted share. The company's financial position remains strong, with $2.5 billion in cash and short-term investments as of December 31, 2013, and a robust operating cash flow of $355 million for the quarter. Management remains focused on strategic investments in research and development and geographic expansion to drive future growth.

Becton Dickinson and Company (BDX) reported its Q3 2013 results, showing a modest revenue increase of 3.6% year-over-year to $2.05 billion. This growth was primarily driven by volume increases, with contributions from the Medical and Diagnostics segments, bolstered by new product sales and acquisitions. However, the company experienced unfavorable foreign currency translation impacts which partially offset revenue gains. Net income for the quarter was $301.6 million, a slight decrease from $326.9 million in the prior year, resulting in diluted EPS of $1.52, down from $1.59. The decrease in profitability was influenced by a $22 million charge related to a settlement in an antitrust class action lawsuit and a $13 million charge for the U.S. medical device excise tax. Despite these headwinds, the company's financial position remains strong, with significant operating cash flows and substantial cash reserves.

Becton, Dickinson and Company (BDX) reported solid revenue growth for the second quarter of fiscal year 2013, with total revenues increasing by 3.7% to $2.0 billion, driven by volume increases across its Medical and Diagnostics segments, partially offset by price decreases and unfavorable foreign currency translation. The company continues to focus on strategic investments in research and development and geographic expansion to fuel long-term growth. Despite a challenging economic environment and pricing pressures in some product lines, BD maintained a strong financial position, with $2.4 billion in cash and short-term investments. The company also returned value to shareholders through share repurchases and dividends. Key financial events during the quarter included the adoption of new accounting guidance for accumulated other comprehensive income, which did not impact consolidated financial statements. The company also announced the acquisition of Cato Software Solutions to enhance its medication safety offerings and Safety Syringes, Inc. to broaden its healthcare worker safety portfolio. These acquisitions are expected to bolster the Medical segment. Furthermore, BD completed the divestiture of its BD Biosciences—Discovery Labware unit, recognizing a significant pre-tax gain. A new medical device excise tax in the U.S. had a notable impact, resulting in a pre-tax charge of $14 million and reducing diluted earnings per share by $0.05 for the quarter.

Becton Dickinson & Co. (BDX) reported strong performance in its first quarter of fiscal year 2013, with revenues increasing by 3.7% year-over-year to $1.9 billion. This growth was driven by solid contributions from the Medical and Diagnostics segments, supported by an early start to the influenza season and continued international demand for safety-engineered products. The company also successfully completed the divestiture of its BD Biosciences—Discovery Labware unit, generating significant cash proceeds and a pre-tax gain. Despite ongoing economic uncertainties and pricing pressures, BDX demonstrated operational improvements, including enhanced gross profit margins attributed to cost-saving initiatives like Project ReLoCo and lower raw material costs. The company continued its commitment to shareholder returns through substantial share repurchases and dividend payments. While facing some legal contingencies and the upcoming impact of the medical device excise tax, BDX's financial position remains robust, with ample liquidity and a strong cash flow from operations.

Becton Dickinson & Co. (BDX) reported its financial results for the fiscal third quarter ended June 30, 2012. The company demonstrated modest revenue growth of 1.5% year-over-year, reaching $1.98 billion, driven by solid performance in its Medical and Diagnostics segments, buoyed by new product introductions and recent acquisitions. However, the Biosciences segment experienced a revenue decline of 2.7%, primarily due to a challenging research spending environment and constrained demand. Despite overall revenue growth, net income saw a slight decrease to $326.9 million from $343.1 million in the prior year's quarter, resulting in diluted earnings per share of $1.59 compared to $1.53 in the prior year. The company continues to invest in R&D and geographic expansion, while also returning value to shareholders through share repurchases and dividends. Management noted that ongoing economic uncertainties, particularly in Europe, and potential impacts from the U.S. healthcare reform, including the medical device excise tax, present ongoing challenges.

Becton Dickinson & Co. (BDX) reported its fiscal second-quarter 2012 results, showcasing modest revenue growth driven by its Medical and Diagnostics segments, partially offset by softer performance in the Biosciences segment. Overall revenue increased by 3.6% year-over-year, attributed to volume increases in medical devices and laboratory equipment, alongside contributions from recent acquisitions. However, the company faced headwinds from pricing pressures in the U.S. market and within certain product lines, as well as increased raw material costs. Financially, BDX maintained a strong liquidity position, with significant cash flow from operations. The company continued its commitment to shareholder returns through share repurchases and dividend payments. A notable event was the acquisition of KIESTRA Lab Automation BV, which is expected to bolster the Diagnostics segment's lab automation solutions. Looking ahead, BDX anticipates ongoing economic challenges and pricing pressures but remains focused on strategic investments in R&D, geographic expansion, and new product development to drive future growth.

Becton, Dickinson and Company (BDX) reported its financial results for the fiscal quarter ended December 31, 2011. The company experienced a modest 2.5% increase in revenue to $1.89 billion, driven by volume growth partially offset by price decreases. While overall revenue grew, operating income saw a decline compared to the prior year, primarily due to increased costs in cost of products sold and selling and administrative expenses, as well as a decrease in operating income from the Medical segment. The company's liquidity remains strong, with significant cash flows from operations and substantial debt issuance to fund corporate purposes. Investors should note the ongoing legal proceedings, particularly the antitrust litigation and patent disputes, which carry potential material adverse effects.

Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter and the first nine months of fiscal year 2011, driven by strong performance in its Medical and Diagnostics segments, particularly in international markets and emerging economies. Despite a challenging global economic environment and some headwinds from healthcare austerity measures in Western Europe, the company demonstrated resilience with a 10% increase in third-quarter revenues to $2.014 billion and a 5% increase for the nine-month period to $5.778 billion. This growth was supported by favorable foreign currency translation, which partially offset price decreases. The company maintained strong operational cash flows, enabling significant investments in share repurchases and dividends, alongside strategic acquisitions. The acquisition of Accuri Cytometers, Inc. in March 2011 is expected to bolster the Biosciences segment. While the company faces ongoing litigation risks and potential impacts from the U.S. healthcare reform, its diversified business model and international presence position it favorably for continued growth.

Becton Dickinson & Co. (BDX) reported its second-quarter and year-to-date results for the period ending March 31, 2011. The company demonstrated revenue growth across its Medical, Diagnostics, and Biosciences segments, driven by volume increases and favorable foreign currency translation. Despite facing some headwinds, including a challenging comparison to the prior year's strong H1N1 sales and the impact of the Japanese earthquake and tsunami, BDX maintained strong operating cash flows. Key financial highlights include robust revenue growth, particularly in international markets and for safety-engineered products, alongside significant share repurchases and dividend payments returning value to shareholders. The company also completed a strategic acquisition of Accuri Cytometers, Inc., aimed at expanding its presence in the flow cytometry market. While managing increased debt levels from recent issuances, BDX's financial condition remains strong, supported by consistent cash generation and ample credit facilities.

Becton Dickinson & Co. (BDX) filed its quarterly report for the period ending December 30, 2010, on February 7, 2011. The filing provides an unaudited look at the company's financial performance and position during the quarter. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) section for detailed insights into operational results, financial condition, and any material changes. The report also includes essential information on legal proceedings, risk factors, and controls and procedures, which are crucial for a comprehensive understanding of the company's current standing and future outlook.

Becton Dickinson & Co. (BDX) filed its 10-Q for the period ending June 29, 2010, highlighting a period of mixed financial performance and ongoing strategic positioning. The company's management discussed its results of operations, financial condition, and potential market risks. Investors should pay close attention to the details within the Condensed Consolidated Statements of Income and Cash Flows to understand the company's revenue generation, cost management, and cash utilization during the quarter. The filing also provides insights into legal proceedings and risk factors that could impact future performance.

Becton Dickinson & Co. (BDX) filed its 10-Q for the period ending March 30, 2010, providing investors with an unaudited snapshot of its financial performance and condition. The report covers the third quarter of the fiscal year, detailing key financial statements and management's analysis. Investors should pay close attention to the company's revenue trends, profitability, and cash flow generation as indicators of its operational health and ability to return value. Key areas of focus for investors will likely include the company's performance across its various business segments, any significant acquisitions or divestitures, and the impact of economic conditions on demand for its products. Understanding the company's liquidity and debt levels is also crucial for assessing financial stability and future growth prospects. The filing also outlines potential risks and legal proceedings that could affect the company's future financial results.

Becton Dickinson & Co. (BDX) reported strong first-quarter results for fiscal year 2010, with revenues increasing by 12% year-over-year to $1.917 billion. This growth was driven by a 9% volume increase and a 3% favorable foreign currency impact, with notable contributions from the Medical and Diagnostics segments, partly due to flu-related sales. Diluted earnings per share from continuing operations rose to $1.30 from $1.25 in the prior year, indicating improved profitability. The company also demonstrated solid cash flow generation, with net cash provided by continuing operating activities at $395 million, an increase from $266 million in the prior year. Despite significant investment in acquisitions, notably HandyLab, Inc., and capital expenditures, BDX maintained a healthy financial position, with total debt representing 24.0% of total capital. Management expressed confidence in its ability to fund ongoing operations, dividends, and share repurchases.

Becton Dickinson & Co. (BDX) reported its third-quarter and nine-month results for the period ending June 30, 2009. The company demonstrated resilience amidst a challenging economic environment, with revenues remaining relatively flat year-over-year for the nine-month period and showing a slight decline in the third quarter. This performance was influenced by a significant unfavorable foreign currency translation impact, partially offset by hedging gains and underlying volume increases. The company also saw an improvement in profitability metrics, with operating income increasing for both the nine-month and third-quarter periods compared to the prior year, driven by improved gross profit margins and disciplined expense management. Key financial highlights include solid income from continuing operations and earnings per share growth, driven by operational efficiencies and a favorable tax settlement. The company also managed its liquidity and capital resources effectively, generating significant cash from operations and maintaining a strong credit profile, despite increased debt levels related to recent note issuances. Investors should note ongoing legal proceedings, particularly the antitrust class action settlement, which has been accounted for in the financial results, and the ongoing divestiture of the Home Healthcare product line. The company continues to invest in research and development to support future growth.